Sells IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH for adults with chronic kidney disease on dialysis, and develops other medicines.
10-K for FY2025, filed Feb 19, 2026Tenapanor, branded as IBSRELA®, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation. We…View ↗
Tenapanor, branded as XPHOZAH®, is approved in the U.S. to reduce serum phosphorus in adults with chronic kidney disease on dialysis as…View ↗
In addition to commercializing IBSRELA and XPHOZAH, we are also developing a next-generation NHE3 inhibitor that we believe can have…View ↗
Ardelyx mainly sells medicines to wholesalers, group purchasing organizations and specialty pharmacies, and product sales are counted when buyers receive the products. Collaboration partners pay license fees upfront, milestone amounts when development or regulatory events occur, royalties on sales, and fees for supplied product.
10-K for FY2025, filed Feb 19, 2026Products are primarily sold to wholesalers, GPOs and specialty pharmacies, and to a lesser extent, directly to retailers, hospitals…View ↗
We apply the ASC 606 five-step process above to the contracts with our Customers. Product revenue is recognized when Customers take control…View ↗
We have entered into collaboration agreements with third parties for the development and commercialization of tenapanor for certain…View ↗
$407.3M
10-K for FY2025, filed Feb 19, 2026
$407.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
93%
FY2022: 30%
|
Product sales, net, FY2025
$377.8M Sources
|
Sold outright |
|
Product supply revenue
Sold outright
|
3.9%
FY2022: 2.9%
|
Product supply revenue, FY2025
$15.9M Sources
|
Sold outright |
|
Licensing revenue
Licensed
|
1.3%
FY2022: 67%
|
Licensing revenue, FY2025
$5.1M Sources
|
Licensed |
|
Non-cash royalty revenue related to the sale of future royalties
|
2.1%
FY2022: 0.0%
|
Non-cash royalty revenue related to the sale of future royalties, FY2025
$8.5M Sources
|
Most medicine sales go to wholesalers, group purchasing organizations and specialty pharmacies; some go directly to retailers, hospitals, clinics and government agencies. Outside the U.S., Ardelyx works with territory partners that develop and commercialize tenapanor.
10-K for FY2025, filed Feb 19, 2026Products are primarily sold to wholesalers, GPOs and specialty pharmacies, and to a lesser extent, directly to retailers, hospitals…View ↗
We have established a high-quality commercial organization, with capabilities, including marketing, market access, patient services and…View ↗
We have entered into collaboration agreements with third parties for the development and commercialization of tenapanor for certain…View ↗
No. It lost $61.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$737KView ↗
10-Q for Q3 FY2026, filed Nov 3, 2026
Open tableView ↗
Growing. Revenue grew 40.3x in 4 years, from $10.1M in FY2021 to $407.3M in FY2025, about 152% a year.
XPHOZAH moved into commercial sales
The older report described XPHOZAH as a medicine in development for kidney patients on dialysis; the latest report says it is approved and marketed for that use.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Feb 19, 2026XPHOZAH was approved by the FDA in October 2023. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the U.S. to reduce…View ↗
Competes with Alebund Pharmaceutical (Hong Kong), Vidasym, Taisho Pharmaceutical, and Unicycive Therapeutics
10-K for FY2025, filed Feb 19, 2026In addition to the currently available phosphate binders, we are aware of at least four phosphate binders in development, including AP-301…View ↗
Loading...